Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation

Summary

People living with human immunodeficiency virus infection (HIV) have 2-4fold greater risk for developing diabetes and heart disease than the general population. They need safe and effective treatments that reduce the risk for developing diabetes and heart disease, and improve their quality of life. This project will explore whether a new anti-diabetes medication (Januvia) with a novel mechanism of action reduces inflammation, and improves blood vessel function in HIV infected men and women with several risk factors for developing cardiovascular disease.

Timeline

Start

2012-10

Primary completion

2014-10

Completion

2014-12

Outcome

Mixed primary results

registry analysis (superiority or other test); Sitagliptin vs Placebo; p = 0.006; t-test, 2 sided NCT01552694 ↗

registry analysis (superiority or other test); Sitagliptin vs Placebo; p = 0.24; t-test, 2 sided NCT01552694 ↗

registry analysis (superiority or other test); Sitagliptin vs Placebo; p = 0.78; t-test, 2 sided NCT01552694 ↗

Publications

• Results Best C, Struthers H, Laciny E, Royal M, Reeds DN, Yarasheski KE. Sitagliptin Reduces Inflammation and Chronic Immune Cell Activation in HIV+ Adults With Impaired Glucose Tolerance. J Clin Endocrinol Metab. 2015 Jul;100(7):2621-9. doi: 10.1210/jc.2015-1531. Epub 2015 May 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sitagliptin	Small molecule	100 mg	Oral

Indications